InvestorsObserver
×
News Home

Is PhaseBio Pharmaceuticals Inc (PHAS) a Good Buy in the Biotechnology Industry?

Monday, June 14, 2021 02:14 PM | InvestorsObserver Analysts

Mentioned in this article

Is PhaseBio Pharmaceuticals Inc (PHAS) a Good Buy in the Biotechnology Industry?

PhaseBio Pharmaceuticals Inc (PHAS) is around the top of the Biotechnology industry according to InvestorsObserver. PHAS received an overall rating of 42, which means that it scores higher than 42 percent of all stocks. PhaseBio Pharmaceuticals Inc also achieved a score of 68 in the Biotechnology industry, putting it above 68 percent of Biotechnology stocks. Biotechnology is ranked 109 out of the 148 industries.

Overall Score - 42
PHAS has an Overall Score of 42. Find out what this means to you and get the rest of the rankings on PHAS!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 42 means the stock is more attractive than 42 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With PhaseBio Pharmaceuticals Inc Stock Today?

PhaseBio Pharmaceuticals Inc (PHAS) stock has gained 3.78% while the S&P 500 has fallen -0.27% as of 2:09 PM on Monday, Jun 14. PHAS has gained $0.14 from the previous closing price of $3.70 on volume of 286,902 shares. Over the past year the S&P 500 is higher by 38.13% while PHAS has fallen -24.41%. PHAS lost -$3.74 per share the over the last 12 months.

Click Here to get the full Stock Score Report on PhaseBio Pharmaceuticals Inc (PHAS) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App